XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical ...

CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA ...

It feels like this shouldn't be happening,' says whistleblower of the clandestine dog testing at St. Joseph's Hospital in ...

How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

OPINION- We have made so many advances in my lifetime, especially as they relate to gender equality, and that includes women’s health. It may not always seem true, but as someone who has witnessed ...

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

Key Points Net loss per share (GAAP) was $(0.30), reflecting a higher loss than prior year. Cash and cash equivalents (GAAP) were $26.8 million, with a pro forma total of about $39 million as of June ...

Discover how AVA brings scale and reproducibility to organ‑chip technology, enabling human‑relevant insights that accelerate ...